These findings link mutations in the KRAS proto-oncogene to the development of pancreatic cancer and place the downstream ERK and AKT signaling pathways as potential therapeutic targets for the development of pharmacologic inhibitors for the treatment of PDAC [5]. This evidence concerns the gene AKT1 and pancreatic neoplasm.